Oncolytic viruses (OVs) now claim a steadily growing market share in cancer therapeutics. These viruses offer an elegant and multimodal mode of action that enables a long-lasting systemic therapeutic success.
m4 Award 2019
PD Dr. Jennifer Altomonte
Teresa Krabbe
Klinikum rechts der Isar, Technical University of Munich
Commercialization of oncolytic viruses (FUSIX Biotech)
Oncolytic viruses (OVs) now claim a steadily growing market share in cancer therapeutics. These viruses offer an elegant and multimodal mode of action that enables a long-lasting systemic therapeutic success. Despite great progress, oncolytic viruses still face some obstacles in aggressive solid tumors and in reaching the tumor during intravenous application. FUSIX Biotech addresses these and other problems with a novel proprietary hybrid virus technology. Based on cell-cell fusion reactions, both the infection of healthy cells and the release of new virus particles from infected cells into the surrounding tissue are reduced, resulting in a special safety profile. With this funding, the team hopes to enable the preclinical development of its lead product.
